CVE:MPH

Medicure Competitors

C$1.60
0.00 (0.00 %)
(As of 04/12/2021 03:59 PM ET)
Add
Compare
Today's Range
C$1.50
Now: C$1.60
C$1.60
50-Day Range
C$1.46
MA: C$1.59
C$1.71
52-Week Range
C$0.70
Now: C$1.60
C$2.80
Volume8,544 shs
Average Volume12,695 shs
Market CapitalizationC$16.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Medicure (CVE:MPH) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying MPH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Medicure, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Medicure (CVE:MPH) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Medicure and Covalon Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Covalon Technologies0000N/A

Profitability

This table compares Medicure and Covalon Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
Covalon TechnologiesN/AN/AN/A

Earnings & Valuation

This table compares Medicure and Covalon Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03
Covalon TechnologiesC$23.84 million1.53C$-6,144,922.00C($0.24)-5.92

Covalon Technologies has higher revenue and earnings than Medicure. Covalon Technologies is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Summary

Covalon Technologies beats Medicure on 4 of the 5 factors compared between the two stocks.

Medicure (CVE:MPH) and Emerald Health Therapeutics (CVE:EMH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Medicure and Emerald Health Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Emerald Health Therapeutics0000N/A

Profitability

This table compares Medicure and Emerald Health Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
Emerald Health TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Medicure and Emerald Health Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38

Medicure has higher earnings, but lower revenue than Emerald Health Therapeutics. Medicure is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Emerald Health Therapeutics beats Medicure on 4 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Medicure (CVE:MPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares IntelGenx Technologies and Medicure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million47.84C$-7,274,150.00C($0.07)-10.15
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03

IntelGenx Technologies has higher earnings, but lower revenue than Medicure. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IntelGenx Technologies and Medicure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
MedicureN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for IntelGenx Technologies and Medicure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Medicure0000N/A

Summary

IntelGenx Technologies beats Medicure on 3 of the 5 factors compared between the two stocks.

Medicure (CVE:MPH) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Medicure and Quest PharmaTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Quest PharmaTech0000N/A

Earnings and Valuation

This table compares Medicure and Quest PharmaTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17

Quest PharmaTech has lower revenue, but higher earnings than Medicure. Medicure is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicure and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Summary

Quest PharmaTech beats Medicure on 4 of the 5 factors compared between the two stocks.

Medicure (CVE:MPH) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Medicure and Ceapro, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Ceapro0000N/A

Earnings and Valuation

This table compares Medicure and Ceapro's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03
CeaproC$16.14 million3.80C$2.56 millionC$0.0323.94

Ceapro has higher revenue and earnings than Medicure. Medicure is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicure and Ceapro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
CeaproN/AN/AN/A

Summary

Ceapro beats Medicure on 5 of the 5 factors compared between the two stocks.

Medicure (CVE:MPH) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Medicure and Crescita Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
Crescita TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Medicure and Crescita Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Crescita Therapeutics0000N/A

Valuation and Earnings

This table compares Medicure and Crescita Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.32C$-16,188,599.00C($1.55)-1.03
Crescita TherapeuticsC$15.64 million1.12C$41,296.00C$0.00425.00

Crescita Therapeutics has higher revenue and earnings than Medicure. Medicure is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Crescita Therapeutics beats Medicure on 4 of the 5 factors compared between the two stocks.


Medicure Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COV
Covalon Technologies
0.6$1.41flatC$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27flatC$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66flatC$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11flatC$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79flatC$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85flatC$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16flatC$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27flatC$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09flatC$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06flatC$11.06 millionC$2.03 million-1.40Gap Down
BTI
Bioasis Technologies
0.7$0.44flatC$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48flatC$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11flatC$7.69 millionN/A-8.75News Coverage
IBT
IBEX Technologies
0.7$0.36flatC$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90flatC$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95flatC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49flatC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32flatC$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.